The research program ILP101 Inhale receives funding for in vivo proof-of-concept testing from The Swedish Cystic Fibrosis Association
The program ILP101 (L. reuteri expressing the mucosal chemokine CXCL17)-Inhale is developed to treat lung infections with MDR pathogens in rare diseases SAVI (STING Associated Vasculophaty with onset in Infancy) and CF (Cystic Fibrosis) and in extension for all people with pneumonia aiming to preserve lung function and be a complement to traditional antibiotics taken orally or i.v..
This grant is given to Prof Mia Phillipson at Uppsala University to support the collaborative program initiated with a Marie Sklodowska-Curie Actions Award where Ilya Pharma and Uppsala University are partners and the program finances Industrial PhD students.
Link to announcement of the award: https://www.rfcf.se/forskningsfonder